Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Thrombin Generation
100%
Hemophilia
61%
Recombinant Activated Factor VII (rFVIIa)
61%
Emicizumab
46%
Bleeding
32%
Activated Protein C
27%
Retina
26%
FEIBA
26%
Patients with Haemophilia
24%
Rotational Thromboelastometry (ROTEM)
24%
Fibrinolysis
24%
Rabbit Model
23%
Corneal Neovascularization
22%
Rat Model
22%
Glanzmann Thrombasthenia
22%
Hemophilia Patients
21%
Clot Formation
20%
Tissue Plasminogen Activator (t-PA)
20%
Hemophilia B
19%
World Data
18%
Tissue Factor
17%
Severe Haemophilia A
17%
Fibrinogen
16%
Factor XI Deficiency
16%
Aflibercept
16%
Riboflavin
16%
Thrombin Generation Assay
14%
Bevacizumab
14%
Conjunctival
13%
Murine Model
13%
Myopic Choroidal Neovascularization (mCNV)
13%
Bypassing Agents
13%
Rare Bleeding Disorders
13%
MCF-7
12%
Platelets
12%
Major Surgery
12%
Bleeding Episodes
12%
Ultraviolet Radiation
11%
High-responding Inhibitors
11%
Activated Prothrombin Complex Concentrates (aPCC)
11%
Thrombin-activatable Fibrinolysis Inhibitor
11%
NLRP3 Inflammasome
11%
Human Breast Cancer Cells
11%
Scleral Crosslinking
11%
Factor VII Deficiency
11%
Basic Fibroblast Growth Factor (bFGF)
11%
Growth Inhibition
11%
Haemophilia with Inhibitors
10%
Surgical Procedures
10%
Factor VIII (FVIII)
10%
Pharmacology, Toxicology and Pharmaceutical Science
Haemophilia A
77%
Thrombin
76%
Emicizumab
45%
Recombinant Blood Clotting Factor 7a
31%
Bleeding
29%
Blood Clotting Factor 11
23%
Blood Clotting Factor 7
23%
Rat Model
22%
Cornea Neovascularization
22%
Activated Protein C
21%
Blood Stasis
20%
Subretinal Neovascularization
19%
Bleeding Disorder
17%
Bevacizumab
17%
Tissue Plasminogen Activator
16%
Aflibercept
16%
Vasculotropin
13%
Activated Prothrombin Complex
12%
Retina Disease
12%
Inflammation
11%
Blood Clotting Factor 8
11%
Breast Cancer
11%
Visual Pigment
11%
Mouse Model
11%
Histone Deacetylase Inhibitor
11%
Haemophilia B
10%
Ciclonicate
10%
Retina Detachment
10%
Blood Clotting Factor 7 Deficiency
9%
Leporidae
9%
Blood Clotting Factor 8 Inhibitor
9%
Fibrinolytic Agent
9%
Replacement Therapy
9%
Blood Clotting Factor
8%
Thromboplastin
8%
Tissue Factor Pathway Inhibitor
8%
Tranexamic Acid
8%
Diseases
7%
Antithrombin
7%
Proliferative Diabetic Retinopathy
7%
Protein C
6%
Fibroblast Growth Factor 2
6%
Rabbit Model
6%
Chemical Burn
6%
Clotting Time
6%
Interleukin 6
5%
Interleukin 1
5%
Messenger RNA
5%
Antifibrinolytic Agent
5%
Glanzmann Disease
5%
Medicine and Dentistry
Haemophilia A
61%
Thrombin
54%
Bleeding
36%
Emicizumab
33%
Patient with Hemophilia
22%
Factor XI
22%
Bleeding Disorder
21%
Hemostat
20%
Blood Stasis
17%
Retinal Detachment
16%
Riboflavin
16%
Cross-Link
16%
Glanzmann's Thrombasthenia
16%
Activated Prothrombin Complex
12%
Thrombosis
12%
Recombinant Blood Clotting Factor 7a
11%
Diseases
11%
Choroidal Neovascularization
11%
Ex Vivo
11%
Retina Disease
11%
Haemophilia B
11%
Corneal Neovascularization
11%
Histone Deacetylase Inhibitor
11%
Myopia
11%
Bleeding Diathesis
10%
Surgical Technique
9%
Endothelial Cell
9%
Substitution Therapy
8%
Blood Clotting Factor 8 Inhibitor
8%
Immunological Tolerance
8%
Blood Clotting Factor 8
7%
Platelet
7%
Ciclonicate
7%
Treatment Option
7%
In Vitro
7%
Thromboelastography
7%
Thromboelastometry
7%
Proliferative Diabetic Retinopathy
7%
Real-World Data
7%
Tissue Factor Pathway Inhibitor
6%
Angiogenesis
6%
Bevacizumab
6%
Thrombocytopenia
6%
Pediatrics
6%
Prospective Study
6%
Antifibrinolytic
6%
D-Dimer
6%
Vitreous
5%
Marstacimab
5%
Microparticle
5%
